Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$16.01 USD

16.01
12,263,833

+0.30 (1.91%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $16.05 +0.04 (0.25%) 5:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (161 out of 246)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

FDA Confirms September Action Date for Teva's Migraine Drug

by Zacks Equity Research

Teva (TEVA) confirms that FDA has extended the goal date of the Biologics License Application (BLA) for fremanezumab to September from mid-June.

    Zacks Equity Research

    Should You Hold Momenta (MNTA) Stock in Your Portfolio?

    by Zacks Equity Research

    Momenta (MNTA) is conducting a strategic review of its ongoing operations as revenues from Glatopa continue to decline.

      Zacks Equity Research

      Amgen's Migraine Drug Aimovig Gets FDA Approval, Shares Up

      by Zacks Equity Research

      Amgen's (AMGN) preventive treatment for migraine, Aimovig, gets approval in the United States.

        Zacks Equity Research

        Company News For May 17, 2018

        by Zacks Equity Research

        Companies In The News are: FOXA,IQV,ABAX,ZTS,TEVA,BRK.B

          Zacks Equity Research

          Eli Lilly's Cluster Headache Candidate Succeeds in Phase III

          by Zacks Equity Research

          Eli Lilly's (LLY) galcanezumab meets the primary endpoint in a late-stage study evaluating it for the prevention of episodic cluster headache.

            Zacks Equity Research

            Teva Stock Up 5% as Buffett's Berkshire Raises Stake in Q1

            by Zacks Equity Research

            Teva's (TEVA) shares gain 5% after Warren Buffett's Berkshire Hathaway reveals an increased stake in the company.

              Zacks Equity Research

              Novartis Multiple Sclerosis Drug Gets FDA Nod for Adolescents

              by Zacks Equity Research

              The FDA approves Novartis' (NVS) multiple sclerosis drug Gilenya for the treatment of children and adolescents aged between 10 and 18.

                Zacks Equity Research

                AstraZeneca's (AZN) Asthma Drug Fasenra Fails in COPD Study

                by Zacks Equity Research

                AstraZeneca's (AZN) asthma drug Fasenra (benralizumab) fails to meet the primary endpoint in a late-stage study evaluating it for a new indication - COPD.

                  Zacks Equity Research

                  BioDelivery (BDSI) Q1 Earnings and Sales Beat Estimates

                  by Zacks Equity Research

                  BioDelivery Sciences' (BDSI) reports narrower-than-expected loss in Q1. Sales marginally beat the consensus mark.

                    Ekta Bagri headshot

                    Mylan (MYL) Q1 Earnings Lag on Weak North America Sales

                    by Ekta Bagri

                    Mylan's first-quarter results were dismal with both earnings and sales missing expectations as challenges in North America persist.

                      Zacks Equity Research

                      Momenta (MNTA) Incurs Wider Y/Y Loss, Glatopa Sales Decline

                      by Zacks Equity Research

                      Momenta reported a wider year-over-year loss in the first quarter. Sales of Glatopa declined due to competition from Mylan.

                        Zacks Equity Research

                        Mylan (MYL) to Report Q1 Earnings: What's in the Offing?

                        by Zacks Equity Research

                        Investors are exepcted to focus on the performance of EpiPen, newly launched drugs and the progress of the company's biosimilars pipeline when Mylan (MYL) reports results for the Q1.

                          Zacks Equity Research

                          Teva (TEVA) Stock Dips Despite Q1 Earnings & Sales Beat

                          by Zacks Equity Research

                          Teva's (TEVA) shares dip despite first-quarter earnings and sales beat. The company raises its 2018 sales and earnings outlook.

                            Kinjel Shah headshot

                            Teva (TEVA) Up on Q1 Earnings & Sales Beat, Rise in Guidance

                            by Kinjel Shah

                            Teva's (TEVA) first-quarter earnings and sales beat expectations. The company raises its 2018 sales and earnings outlook. Stock up in pre-market trading.

                              Zacks Equity Research

                              Teva (TEVA) to Report Q1 Earnings: What's in the Cards?

                              by Zacks Equity Research

                              Teva's (TEVA) Generics segment sales are likely to be weak due to increased pricing erosion while loss of exclusivity of key drugs like Copaxone is likely to hurt sales of the Specialty segment.

                                Zacks Equity Research

                                Novartis (NVS) Reports Encouraging Data on MS Candidate

                                by Zacks Equity Research

                                Novartis (NVS) announces encouraging results from a phase III study, EXPAND, on siponimod (BAF312) in patients with secondary progressive multiple sclerosis.

                                  Zacks Equity Research

                                  Amgen's Aimovig Reduces Episodic Migraine in 30% Patients

                                  by Zacks Equity Research

                                  Amgen (AMGN) releases full data from the phase IIIb trial, evaluating the efficacy and safety of Aimovig on patients suffering episodic migraine with multiple treatment failures.

                                    Zacks Equity Research

                                    Mylan Inks Deal with Mapi Pharma for Multiple Sclerosis Drug

                                    by Zacks Equity Research

                                    Mylan (MYL) has inked a deal with Israel based Mapi Pharma to acquire its multiple sclerosis candidate.

                                      Zacks Equity Research

                                      AbbVie (ABBV) Stock Falls on Weak Lung Cancer Study Outcome

                                      by Zacks Equity Research

                                      AbbVie's (ABBV) key lung cancer candidate, Rova-T falls short in a phase II study. AbbVie will not seek accelerated approval of Rova-T in the third-line setting

                                        Zacks Equity Research

                                        BioDelivery (BDSI) Q4 Loss Wider-Than-Expected, Sales Up Y/Y

                                        by Zacks Equity Research

                                        BioDelivery (BDSI) reports wider-than-expected loss in Q4. However, revenues surpass estimates and increase substantially year over year.

                                          Zacks Equity Research

                                          Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals

                                          by Zacks Equity Research

                                          Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals

                                            Zacks Equity Research

                                            Pharma Stocks Weighed Down by Competition, Generic Pressure

                                            by Zacks Equity Research

                                            Although pharma and biotech sectors rebounded in 2017 and started 2018 on an optimistic note, drug companies may find it a bit difficult to justify their high prices.

                                              Zacks Equity Research

                                              Can New Approvals Help Mylan Stock Turn Around in 2018?

                                              by Zacks Equity Research

                                              Mylan (MYL) faced challenging conditions in 2017 but 2018 is expected to be better driven by new product launches.

                                                Zacks Equity Research

                                                Pharmaceutical Industry Outlook - March 2018

                                                by Zacks Equity Research

                                                The year 2017 was rewarding for pharma and biotech stocks, with the sector witnessing some positive developments that led to a much-awaited recovery.

                                                  Zacks Equity Research

                                                  Mylan (MYL) Q4 Earnings Surpass Estimates, Revenues Miss

                                                  by Zacks Equity Research

                                                  Mylan???s (MYL) mixed Q4 results show earnings beat but revenues miss on pricing pressure and weak EpiPen sales.